학술논문
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
Document Type
article
Author
Florent Malard; Myriam Labopin; Christina Cho; Didier Blaise; Esperanza B. Papadopoulos; Jakob Passweg; Richard O’Reilly; Edouard Forcade; Molly Maloy; Liisa Volin; Hugo Castro-Malaspina; Yosr Hicheri; Ann A. Jakubowski; Corentin Orvain; Sergio Giralt; Mohamad Mohty; Arnon Nagler; Miguel-Angel Perales
Source
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-11 (2018)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Background Graft-versus-host disease (GVHD) is one of the leading causes of non-relapse mortality and morbidity after allogeneic hematopoietic stem cell transplantation (allo-HCT). Methods We evaluated the outcomes of two well-established strategies used for GVHD prevention: in vivo T cell depletion using antithymocyte globulin (ATG) and ex vivo T cell depletion using a CD34-selected (CD34+) graft. A total of 525 adult patients (363 ATG, 162 CD34+) with intermediate or high-risk cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1) were included. Patients underwent myeloablative allo-HCT using matched related or unrelated donors. Results Two-year overall survival estimate was 69.9% (95% CI, 58.5–69.4) in the ATG group and 67.6% (95% CI, 60.3–74.9) in the CD34+ group (p = 0.31). The cumulative incidence of grade II–IV acute GVHD and chronic GVHD was higher in the ATG cohort [HR 2.0 (95% CI 1.1–3.7), p = 0.02; HR 15.1 (95% CI 5.3–42.2), p